CNS Summit 2013, Boca Raton, FL Christopher Missling, Tangui Maurice, Athan Spiros, Patrick Roberts and Hugo Geerts View Poster Post navigationPreviousPrevious post:Anavex Appoints Clinical Design Expert to Scientific Advisory BoardNextNext post:Anavex CEO Invited to Present at Upcoming Investment ConferencesRelated PostsAnavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare ConferenceSeptember 18, 2019Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett SyndromeSeptember 16, 2019Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett SyndromeSeptember 4, 2019Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett SyndromeJuly 31, 2019
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare ConferenceSeptember 18, 2019
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett SyndromeSeptember 16, 2019
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett SyndromeSeptember 4, 2019
Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett SyndromeJuly 31, 2019
